Evaluating [

Andrea Di Giorgio, Marco Rapa, Simona Civollani, Andrea Farolfi, Stefano Fanti

Abstract read

In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Post-Treatment Imaging in Focal Therapy: Understanding TARGET and PI-FAB Scoring Systems.Diagnostics (Basel, Switzerland) · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrea Di GiorgioNuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.ORCID 0009-0006-3973-4409

Marco RapaNuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

Simona CivollaniDepartment of Medical Physics, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Andrea FarolfiNuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, 40138 Bologna, Italy.ORCID 0000-0002-5443-4301

Stefano FantiNuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.ORCID 0000-0003-1486-2624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal therapy offers a promising approach for treating localized prostate cancer (PC) with minimal invasiveness and potential cost benefits. High-intensity focused ultrasound (HIFU) and brachytherapy (BT) are among these options but lack long-term efficacy data. Patient follow-ups typically use biopsies and multiparametric MRI (mpMRI), which often miss recurrences. PET/CT with PSMA has emerged as a promising tool for detecting residual disease or recurrence post-treatment, offering higher sensitivity and specificity than traditional imaging. We retrospectively reviewed patients who underwent [

Indexed as

BrachytherapyHigh-Intensity Focused Ultrasound AblationNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overEdetic AcidGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedOligopeptidesRetrospective StudiesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesbrachytherapyHIFUnuclear medicineoncologyPETprostate cancerPSMA

Identifiers

PMID39851925

DOI10.3390/curroncol32010009

PMCPMC11763418

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.